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the base rate for use of ACE inhibitors was 20%; and the rates for symptoms leading to testing were 4% if the GFR was 90, 30% if the GFR was 15 to 89, and 100% if the GFR was less than 15. The authors assumed the last two values.
The base rate used for potential benefits of screening all sub-groups was a 30% relative risk reduction in progression toward ESRD, and a 23% reduction in all-cause mortality. Reductions afforded by ACE inhibitor or ARB were assumed to be equal.
The base rates used for potential harm of screening were as follows.
renal biopsy rates were 90% for persons with neither hypertension nor diabetes, 5% for persons with hypertension and 5% for persons with diabetes;
complications due to renal biopsy (including haematuria, clinical haematoma, and other complications) were 5%; medication adverse effect rates included a rate of 0.5% for anaphylaxis secondary to ACE inhibitor or ARB, and a rate of 2% for angioedema secondary to ACE inhibitor.
See the original paper for the rates of annual decline in glomerular filtration.
Methods used to derive estimates of effectiveness
This analysis was based on published data and authors' assumptions.
Estimates of effectiveness and key assumptions
The model assumptions were as follows.
For persons with neither hypertension nor diabetes and with no proteinuria, rates of GFR decline from 15 to 89 mL/minute per 1.73 m2 (KDOQI stage 2-4) to less than 15 mL/minute per 1.73 m2 (KDOQI stage 5) were the same as rates of GFR decline for persons with normal kidney function (KDOQI stage 1). Among persons with neither hypertension nor diabetes and with proteinuria, the rates of GFR decline for persons with a GFR of 90 mL/minute per 1.73 m2 (KDOQI stage 1) were 10% greater than the rates for their counterparts with no proteinuria. Among persons with hypertension and with no proteinuria, the rates of GFR decline for persons with normal kidney function (KDOQI stage 1) were 10% greater than the rates for persons with neither hypertension nor diabetes and with no proteinuria.
Proteinuria is generally asymptomatic and is associated with a minimal decrement in health status.
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). The health state utilities were drawn from other research (Tengs et al., see Other Publications of Related Interest). The only methodology reported was that the standard gamble or time-tradeoff technique was used. The disutility associated with ACE inhibitor or ARB therapy was estimated from data reporting the adverse effects of medication. The QALYs were discounted at a rate of 3% per year.
Direct costs
The direct costs to the health service were included and were appropriately discounted at a rate of 3% per year. These included initial testing and follow-up visits, therapeutic costs, medication adverse events and ESRD treatment costs. The test costs were estimated using Medicare reimbursement rates based on the Medicare resource-based relative value scale for part B services. The costs of ACE inhibitor or ARB therapy were estimated by using a weighted average of the wholesale prices for proprietary and non-proprietary products on the market. The costs of emergency department visits were estimated using data from the Centres for Medicare and Medicaid services. The costs of treating ESRD (KDOQI stage 5) were estimated using data from the US Renal Data System. All the direct costs were in year 2002 dollars. 
Statistical analysis of costs
The costs were treated deterministically and no statistical tests were carried out.
Indirect Costs
The indirect costs of wages lost for persons unable to work as a result of ESRD were included and were discounted at a rate of 3% per year. The annual lost wages for nonworking persons with ESRD (KDOQI stage 5) were estimated using a weighted average of published estimates of the mean percentage of persons working full-time while receiving either dialysis or transplantation treatment modalities. Persons in all other stages were considered to be working full-time until they turned 65 years. The data on average US wages were taken from the US Department of Labour. All the indirect costs were in year 2002 dollars.
Currency
US dollars ($).
Sensitivity analysis
The Markov model was analysed using cohort simulations for base-case and several sensitivity analyses. Analyses were carried out on the optimal age for screening (beginning screening at ages 30 to 70 years) and the optimal frequency of screening (from annually to every 10 years). One-way sensitivity analyses were also performed on all model parameters.
Each parameter was given values to bias them in favour of or against screening. A change ratio of 50% or more was considered highly influential.
For the multi-way sensitivity analysis, a Monte Carlo analysis consisting of 1,000 simulations in which all parameters were varied simultaneously over their distributions was performed. The types of distribution used were not reported.
Estimated benefits used in the economic analysis
The base-case gain in discounted QALYs for screening was 0.0022. One new case of ESRD and 7 deaths per 1 million persons per year in the screening strategy were prevented. The QALYs were discounted at a rate of 3% per year.
Cost results
For persons with neither hypertension nor diabetes, when considering benefits in both death and chronic kidney disease progression, the total cost of the screening strategy was $13,745 versus $13,129 for the usual care strategy. The incremental cost was $616.
For persons with hypertension, when considering benefits in both death and chronic kidney disease progression, the total cost of the screening strategy was $23,927 versus $23,451 for the usual care strategy. The incremental cost was $476.
For persons with neither hypertension nor diabetes, when considering the benefit in life extension only, the total cost of the screening strategy was $13,766 versus $13,131 for the usual care strategy. The incremental cost was $635.
For persons with hypertension, when considering the benefit in life extension only, the total cost of the screening strategy was $24,194 versus $23,496 for the usual care strategy. The incremental cost was $697. For persons with neither hypertension nor diabetes, when considering the benefit in chronic kidney disease progression only, the total cost of the screening strategy was $13,128 versus $13,740 for the usual care strategy. The incremental cost was $612.
For persons with hypertension, when considering the benefit in chronic kidney disease progression only, the total cost of the screening strategy was $23,865 versus $23,443 for the usual care strategy. The incremental cost was $422.
Synthesis of costs and benefits
The base-case cost-effectiveness ratio for screening versus the usual care strategy (no screening) was unfavourable ($282, 218 per QALY saved) .
For persons with hypertension, the cost-effectiveness ratio for the screening strategy versus no screening was highly favourable ($18,621 per QALY saved).
For persons with diabetes, the screening strategy was dominant over the no screening strategy (savings of $217 and a gain of 0.10 QALYs per person in the screening strategy).
The results of the sensitivity analyses were as follows.
For persons with neither hypertension nor diabetes, the cost-effectiveness of screening was unfavourable until screening beginning at age 60 years. For persons with hypertension, annual screening beginning at age 30 years resulted in highly favourable cost-effectiveness ratios.
Decreasing the frequency of screening in the base-case for persons with neither hypertension nor diabetes resulted in more favourable cost-effectiveness ratios ($120,727 every 5 years and $80,700 every 10 years). Similar results were found for screening persons of older ages at different intervals. For persons with hypertension, screening at less frequent intervals resulted in improved cost-effectiveness for all age groups.
For persons with neither hypertension nor diabetes, screening approached moderately favourable cost-effectiveness if the incidence of proteinuria was set to its greatest extreme and the frequency of screening was set to its smallest extreme. The cost-effectiveness of screening persons with hypertension remained highly favourable for all variables biased against screening at their extremes.
The multi-way Monte Carlo analysis supported the base-case results.
For persons with neither diabetes nor hypertension, the proportion of simulations in which screening yielded costeffectiveness ratios of less than $50,000 per QALY was 1.5%.
For persons with hypertension, the proportion of simulations in which screening yielded cost-effectiveness ratios of less than $50,000 per QALY was 50.3%.
